United Therapeutics (UTHR) CEO exercises options and sells 9,500 shares in 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
United Therapeutics Chairperson and CEO Martine Rothblatt reported a mix of option exercises and stock sales. On March 3, 2026, she exercised 9,500 stock options, receiving an equal number of common shares, then sold 9,500 common shares in multiple open-market transactions.
These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. After the reported sales, she directly held 130 common shares, in addition to indirect holdings through her spouse and family trusts.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 9,500 shares ($4,744,467)
Net Sell
23 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($4.74M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 9,500 | $0.00 | -- |
| Exercise | Common Stock | 9,500 | $146.03 | $1.39M |
| Sale | Common Stock | 283 | $491.6827 | $139K |
| Sale | Common Stock | 340 | $492.5343 | $167K |
| Sale | Common Stock | 456 | $493.7095 | $225K |
| Sale | Common Stock | 680 | $494.7521 | $336K |
| Sale | Common Stock | 555 | $495.8727 | $275K |
| Sale | Common Stock | 407 | $496.7096 | $202K |
| Sale | Common Stock | 1,075 | $498.0113 | $535K |
| Sale | Common Stock | 1,371 | $498.955 | $684K |
| Sale | Common Stock | 1,058 | $499.8547 | $529K |
| Sale | Common Stock | 495 | $500.9604 | $248K |
| Sale | Common Stock | 379 | $501.9316 | $190K |
| Sale | Common Stock | 210 | $503.0318 | $106K |
| Sale | Common Stock | 730 | $503.9923 | $368K |
| Sale | Common Stock | 908 | $505.0591 | $459K |
| Sale | Common Stock | 132 | $506.1572 | $67K |
| Sale | Common Stock | 421 | $507.0903 | $213K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 221,000 shares (Direct);
Common Stock — 9,630 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (1)
- This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. This transaction was executed in multiple trades at prices ranging from $499.43 to $500.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $500.43 to $501.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $501.51 to $502.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $502.51 to $503.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $503.51 to $504.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $504.69 to $505.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $505.85 to $506.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $507.02 to $507.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. This transaction was executed in multiple trades at prices ranging from $491.09 to $492.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. This transaction was executed in multiple trades at prices ranging from $492.17 to $493.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $493.17 to $494.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $494.20 to $495.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $495.32 to $496.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $496.33 to $497.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $497.43 to $498.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $498.43 to $499.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
FAQ
What insider transactions did United Therapeutics (UTHR) CEO Martine Rothblatt report?
Martine Rothblatt reported exercising 9,500 stock options and receiving 9,500 United Therapeutics common shares, then selling 9,500 common shares in multiple open-market trades on March 3, 2026. The filing also updates her remaining direct and indirect share holdings.
Was the United Therapeutics (UTHR) CEO’s recent stock sale pre-planned?
Yes. The option exercise and resulting stock sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. That plan automates trades according to preset instructions rather than day-to-day market decisions by the executive.
How many United Therapeutics (UTHR) stock options are covered by the CEO’s trading plan?
The trading plan will continue until the earlier of exercising 1,734,410 United Therapeutics stock options, all expiring on March 17, 2027, or December 31, 2026. This figure reflects the remaining options potentially subject to sales under the plan’s terms.